## BRISTOL-MYERS SQUIBB COMPANY WORLDWIDE REVENUES QUARTERLY REVENUES TREND ANALYSIS (Unaudited, dollars in millions)

	2018							2019							\$ Change		% Change	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr <sup>(b)</sup>	Year <sup>(b)</sup>	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Prioritized Brands																		
Revlimid	s —	\$ —	\$ —	\$ —	\$ —	s —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$1,299	\$1,299	\$1,299	\$1,299	N/A	N/A
Eliquis	1,506	1,650	3,156	1,577	4,733	1,705	6,438	1,925	2,042	3,967	1,928	5,895	2,034	7,929	329	1,491	19%	23%
Opdivo	1,511	1,627	3,138	1,793	4,931	1,804	6,735	1,801	1,823	3,624	1,817	5,441	1,763	7,204	(41)	469	(2)%	7%
Orencia	593	711	1,304	675	1,979	731	2,710	640	778	1,418	767	2,185	792	2,977	61	267	8%	10%
Pomalyst/Imnovid	_	_	_	_	_	_	_	_	_	-	_	_	322	322	322	322	N/A	N/A
Sprycel	438	535	973	491	1,464	536	2,000	459	544	1,003	558	1,561	549	2,110	13	110	2%	6%
Yervoy	249	315	564	382	946	384	1,330	384	367	751	353	1,104	385	1,489	1	159	_	12%
Abraxane	_	_	_	_	_	_	_	_	_	_	_	_	166	166	166	166	N/A	N/A
Empliciti	55	64	119	59	178	69	247	83	91	174	89	263	94	357	25	110	36%	45%
Inrebic	_	_	_	_	_	_	_	_	_	_	_	_	5	5	5	5	N/A	N/A
Established Brands																		
Baraclude	225	179	404	175	579	165	744	141	147	288	145	433	122	555	(43)	(189)	(26)%	(25)%
Vidaza	_	_	_	_	_	_	_	_	_	_	_	_	58	58	58	58	N/A	N/A
Other Brands <sup>(a)</sup>	616	623	1,239	539	1,778	579	2,357	487	481	968	350	1,318	356	1,674	(223)	(683)	(39)%	(29)%
Total	\$5,193	\$5,704	\$10,897	\$5,691	\$16,588	\$5,973	\$22,561	\$5,920	\$6,273	\$12,193	\$6,007	\$18,200	\$7,945	\$26,145	\$1,972	\$3,584	33%	16%

<sup>(</sup>a) Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes \$37 million relating to Celgene products from November 20, 2019 through December 31, 2019.

<sup>(</sup>b) Includes Celgene product revenues from November 20, 2019 through December 31, 2019.